The ROE as of November 2024 (TTM) for NeuBase Therapeutics, Inc. (NBSE) is -107.92%

According to NeuBase Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -107.92%. This represents a change of 307.28% compared to the average of -26.50% of the last 4 quarters.

NeuBase Therapeutics, Inc. (NBSE) Historical ROE (quarterly & annually)

How has NBSE ROE performed in the past?

The mean historical ROE of NeuBase Therapeutics, Inc. over the last ten years is -102.65%. The current -107.92% ROE has changed 5.13% with respect to the historical average. Over the past ten years (40 quarters), NBSE's ROE was at its highest in in the June 2018 quarter at -3.17%. The ROE was at its lowest in in the September 2019 quarter at -237.15%.

NeuBase Therapeutics, Inc. (NBSE) ROE by Quarter and Year

Discovering the peaks and valleys of NeuBase Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

NeuBase Therapeutics, Inc. (NBSE) Average ROE

How has NBSE ROE performed in the past?

The current ROE of NeuBase Therapeutics, Inc. (NBSE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

NeuBase Therapeutics, Inc. (NBSE) ROE vs. Peers

How is NBSE’s ROE compared to its peers?

NeuBase Therapeutics, Inc.’s ROE is greater than Immix Biopharma, Inc. (-86.48%), less than CNS Pharmaceuticals, Inc. (428.91%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Navidea Biopharmaceuticals, Inc. (-173.56%), greater than Sonnet BioTherapeutics Holdings, Inc. (-398.33%), less than Kiromic BioPharma, Inc. (0%), less than ZyVersa Therapeutics, Inc. (337.72%), greater than YS Biopharma Co., Ltd. (-172.51%), greater than BiomX Inc. (-50.46%), greater than Landos Biopharma, Inc. (-121.74%), greater than Apexigen, Inc. (-73.00%), greater than Angion Biomedica Corp. (-606.56%), greater than Monte Rosa Therapeutics, Inc. (-113.71%), greater than NewAmsterdam Pharma Company N.V. (-70.40%), greater than Inventiva S.A. (-86.66%), less than Cullinan Oncology, Inc. (550.46%), greater than Compass Therapeutics, Inc. (-28.37%), greater than null (-28.67%),

Build a custom stock screener for NeuBase Therapeutics, Inc. (NBSE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NeuBase Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

NeuBase Therapeutics, Inc. (NBSE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like NeuBase Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.